|
Diaverum welcomes M42 as
its new shareholder
(Malmö, Sweden and
Abu Dhabi, UAE) -
Diaverum has announced
that
M42 has entered into a
definitive agreement to
acquire 100% of the company
from Bridgepoint.
Diaverum, acquired by
Bridgepoint in 2007, is a
leading global renal care
company that provides
essential, life-sustaining
dialysis treatments to
patients in around 440
clinics across 23 countries
worldwide. The company’s
main focus is hemodialysis,
in conjunction with a
portfolio of treatments
ranging from preventive
care, peritoneal dialysis
and home care to the
coordination of patients’
comorbidities and their
preparation for kidney
transplantation.
Diaverum has an extensive
in-house proficiency in
digital transformation and
Artificial Intelligence (AI)
applications. Its
proprietary digital care
delivery model drives
increased patient longevity
and reduces hospitalization,
while also contributing to
operational efficiency and
growth. Diaverum is
supported by a dedicated
Management team with broad
international healthcare
experience, who are
committed to improving
medical outcomes for
patients and continuing to
drive innovation in digital
care delivery.
M42 is
an Abu Dhabi-based global
tech-enabled healthcare
holding company. Established
after the coming together of
G42 Healthcare and Mubadala
Health, M42 combines unique
medical and data-centric
technologies with
state-of-the-art facilities
to deliver the highest level
of precise, patient-centric
and preventive care.
Diaverum represents a
landmark strategic
investment for M42 as both
companies share a focus on
specialty healthcare, with
an aim to be at the
forefront of integrating AI
and technology into patient
care. The combination of M42
and Diaverum represents an
opportunity to leverage both
companies’ clinical
excellence and cutting-edge
technological expertise to
expand healthcare services
and healthtech solutions
across both existing and new
markets.
Dimitris Moulavasilis, CEO
of Diaverum, said:
“We are pleased to join
M42’s integrated global
network. M42 is a perfect
fit for Diaverum’s future,
and the combination of the
two organizations will
further strengthen our
position as a global leader
in renal care. Together,
we’ll be in an even greater
position to drive
international growth and
continue transforming the
industry through
patient-centric digital
innovations while delivering
and broadening access to the
highest quality renal care.
I would also like to express
my gratitude to Diaverum’s
employees across the world,
who make a difference in our
patients’ lives every single
day. They have been integral
in developing Diaverum and
successfully supporting this
transaction.”
Hasan Jasem Al Nowais, CEO
of M42, said:
“M42’s acquisition of
Diaverum represents a major
milestone in our global
expansion strategy. Diaverum
is an exceptional company,
providing vital treatments
that enable patients
suffering from chronic
kidney disease to live
fulfilling lives. Its
pioneering digital care
offering fully aligns with
M42’s focus on leveraging
advanced technological
solutions to deliver
precise, personalized
patient care. I look forward
to working with Diaverum’s
management team to address
the critical challenge that
chronic kidney disease
represents to countries’
healthcare services around
the world.”
The deal,
which is subject to
customary regulatory
approvals, is expected to
close in the second half of
2023.
Citigroup acted
as exclusive financial
advisor, White & Case as
legal advisor, KPMG as
financial and tax advisor,
and LEK as commercial
advisor in the transaction.
PRINT
THIS ARTICLE
font>/a>br>
|